Synthetic Design Lab develops next‑generation antibody‑drug conjugates (ADCs) using its SYNTHBODY™ platform, which creates engineered synthetic targets that detect specific combinations of cancer cell surface proteins. The platform’s multilayered BIO‑LOGIC™ control and multivalent, multispecific design enable payload delivery that is at least ten times more efficient than traditional IgG‑based ADCs, improving potency and safety for hard‑to‑treat cancers.
Funding
$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current antibody‑drug conjugates (ADCs) rely on conventional IgG platforms that target single proteins, limiting payload delivery efficiency, specificity, and the ability to address complex tumor biology. This results in suboptimal potency and safety for patients with hard‑to‑treat cancers.
Solution
Synthetic Design Lab’s SYNTHBODY™ platform creates engineered “synthetic targets” by detecting specific combinations of surface proteins on cancer cells and applying multilayered BIO‑LOGIC™ control. This enables multivalent, multispecific ADCs that deliver payloads with ≥10‑fold higher targeting efficiency while coordinating conditional biologic signals across multiple pathways. The platform’s logic gates (AND‑BETTER, OR, MULTIPLIERS, etc.) provide precise spatial, temporal, and physiological control, improving potency and safety beyond what natural antibody biology permits. By integrating multifunctionality without trade‑offs, SYNTHBODY™ expands therapeutic possibilities for difficult‑to‑treat malignancies.
Target Audience
Primary customers are biopharmaceutical companies and oncology drug developers seeking next‑generation ADC technologies for hard‑to‑treat cancers.
Features
- Multilayered BIO‑LOGIC™ control with advanced logic gates (AND‑BETTER, OR, MULTIPLIERS, spatial/temporal cues)
- Multivalent, multispecific design that detects combinations of tumor surface proteins to create synthetic targets
- Optimized payload delivery achieving ≥10× higher targeting efficiency compared to traditional ADCs
- Integrated coordination of multiple biologic pathways for enhanced therapeutic effect
- Engineered platform enables rapid development of next‑generation ADC candidates tailored to specific cancer indications